ReviewNature reviews. Clinical oncology2017
Imaging biomarker roadmap for cancer studies.
Abstract readConsensus StatementReview
In one paragraph
Review in Nature reviews. Clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 589 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
589citing papers in PubMed, 8 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
589 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Image Quality Standardization in Radiomics: A Systematic Review of Artifacts, Variability, and Feature Stability.Sensors (Basel, Switzerland) · 2026Pooled it
- Application and integration of deep learning in tumour radiomics: bibliometrics and visualisation analysis.Frontiers in artificial intelligence · 2026Pooled it
- The scientific evidence of commercial AI products for MRI acceleration: a systematic review.European radiology · 2025Pooled it
- MRI radiomics in diagnosing high and low grade meningiomas through systematic review and meta analysis.Scientific reports · 2025Pooled it
- Radiomics and ischemic stroke research: bibliometric insights and visual trends (2004-2024).Frontiers in neurology · 2025Pooled it
- Radiomics in precision medicine for colorectal cancer: a bibliometric analysis (2013-2023).Frontiers in oncology · 2024Pooled it
- Radiomics based on MRI in predicting lymphovascular space invasion of cervical cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- A systematic review of radiomics in giant cell tumor of bone (GCTB): the potential of analysis on individual radiomics feature for identifying genuine promising imaging biomarkers.Journal of orthopaedic surgery and research · 2023Pooled it
- CT staging performance in an international trial of neoadjuvant chemotherapy for locally advanced colon cancer.The British journal of radiology · 2025Trial
- An Expanded T2-FLAIR Mismatch Phenotype in IDH-Mutant Astrocytomas.Journal of magnetic resonance imaging : JMRI · 2026Article
- Precision of Ablation Margin Assessment After Liver Microwave Ablation: A Head-to-Head Comparison of Visual and Software-Assisted Methods.Cardiovascular and interventional radiology · 2026Article
- The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Letter to the Editor: ADC as a non-invasive surrogate for PD-L1 in cervical cancer-addressing potential confounding and the leap to immunotherapy selection.European radiology · 2026Article
- Reply to the Letter to the Editor: ADC as a non-invasive surrogate for PD-L1 in cervical cancer-addressing potential confounding and the leap to immunotherapy selection.European radiology · 2026Article
- Seeing Angiogenesis: Multiparametric Ultrasound as a Non-Invasive Window into the Vascularization Status of Cervical Lymph Nodes in Head and Neck Squamous Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2026Review
- Tumor metrics imaging core labs: primer for radiologists.Abdominal radiology (New York) · 2026Review
- Redefining Soft Tissue Sarcoma Imaging: The Expanding Role of Positron Emission Tomography/Computed Tomography: A Review.World journal of nuclear medicine · 2026Review
- Theranostic π Electron-Stabilized Polymeric Micelles for PET Imaging-Guided Drug Delivery to Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Liver metastases beyond classical imaging findings.Abdominal radiology (New York) · 2026Review
- Cerebrovascular reactivity delay measured by blood oxygen level dependent magnetic resonance imaging and gas challenges: A systematic review.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Review
529 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
77 authors.
James P B O'ConnorCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Manchester, Manchester, UK.
Eric O AboagyeDepartment of Surgery and Cancer, Imperial College, London, UK.
Judith E AdamsDepartment of Clinical Radiology, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Hugo J W L AertsDepartment of Radiation Oncology, Harvard Medical School, Boston, MA.
Sally F BarringtonCRUK and EPSRC Comprehensive Imaging Centre at KCL and UCL, Kings College London, London, UK.
Ambros J BeerDepartment of Nuclear Medicine, University Hospital Ulm, Ulm, Germany.
Ronald BoellaardDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
Sarah E BohndiekCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Cambridge, Cambridge, UK.
Michael BradyCRUK and EPSRC Cancer Imaging Centre, University of Oxford, Oxford, UK.
Gina BrownRadiology Department, Royal Marsden Hospital, London, UK.
David L BuckleyDivision of Biomedical Imaging, University of Leeds, Leeds, UK.
Thomas L ChenevertDepartment of Radiology, University of Michigan, Ann Arbor, MI.
Laurence P ClarkeCancer Imaging Program, National Cancer Institute, Bethesda, MD.
Sandra ColletteBiostatistics, EORTC, Brussels, Belgium.
Gary J CookCRUK and EPSRC Comprehensive Imaging Centre at KCL and UCL, Kings College London, London, UK.
Nandita M deSouzaCRUK Cancer Imaging Centre, The Institute of Cancer Research, London, UK.
John C DicksonCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Caroline DiveClinical and Experimental Pharmacology, CRUK Manchester Institute, Manchester, UK.
Jeffrey L EvelhochTranslational Biomarkers, Merck &Co., Inc, West Point, PA.
Corinne Faivre-FinnRadiotherapy Related Research Group, University of Manchester, Manchester, UK.
Ferdia A GallagherCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Cambridge, Cambridge, UK.
Fiona J GilbertCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Cambridge, Cambridge, UK.
Robert J GilliesCancer Imaging and Metabolism, Moffitt Cancer Center, Tampa, FL.
Vicky GohCRUK and EPSRC Comprehensive Imaging Centre at KCL and UCL, Kings College London, London, UK.
John R GriffithsCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Cambridge, Cambridge, UK.
Ashley M GrovesCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Steve HalliganCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Adrian L HarrisCRUK and EPSRC Cancer Imaging Centre, University of Oxford, Oxford, UK.
David J HawkesCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Otto S HoekstraDepartment of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Erich P HuangBiometric Research Program, National Cancer Institute, Bethesda, MD.
Brian F HuttonCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Edward F JacksonDepartment of Medical Physics, University of Wisconsin, Madison, WI.
Gordon C JaysonInstitute of Cancer Sciences, University of Manchester, Manchester, UK.
Andrew JonesMedical Physics, The Christie Hospital NHS Foundation Trust, Manchester, UK.
Dow-Mu KohCRUK Cancer Imaging Centre, The Institute of Cancer Research, London, UK.
Denis LacombeEORTC Headquarters, EORTC, Brussels, Belgium.
Philippe LambinDepartment of Radiation Oncology, University of Maastricht, Maastricht, Netherlands.
Nathalie LassauDepartment of Imaging, Gustave Roussy Cancer Campus, Villejuif, France.
Martin O LeachCRUK Cancer Imaging Centre, The Institute of Cancer Research, London, UK.
Ting-Yim LeeImaging Research Labs, Robarts Research Institute, London, Ontario, Canada.
Edward L LeenDepartment of Surgery and Cancer, Imperial College, London, UK.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
Yan LiuEORTC Headquarters, EORTC, Brussels, Belgium.
Mark F LythgoeCentre for Advanced Biomedical Imaging, University College London, London, UK.
Prakash ManoharanCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Manchester, Manchester, UK.
Ross J MaxwellNorthern Institute for Cancer Research, Newcastle University, Newcastle, UK.
Kenneth A MilesCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Bruno MorganCancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.
Steve MorrisInstitute of Epidemiology and Health, University College London, London, UK.
Tony NgCRUK and EPSRC Comprehensive Imaging Centre at KCL and UCL, Kings College London, London, UK.
Anwar R PadhaniPaul Strickland Scanner Centre, Mount Vernon Hospital, London, UK.
Geoff J M ParkerCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Manchester, Manchester, UK.
Mike PartridgeCRUK and EPSRC Cancer Imaging Centre, University of Oxford, Oxford, UK.
Arvind P PathakDepartment of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Andrew C PeetInstitute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
Shonit PunwaniCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Andrew R ReynoldsBreakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
Simon P RobinsonCRUK Cancer Imaging Centre, The Institute of Cancer Research, London, UK.
Lalitha K ShankarCancer Imaging Program, National Cancer Institute, Bethesda, MD.
Ricky A SharmaCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Dmitry SolovievCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Cambridge, Cambridge, UK.
Sigrid StroobantsMolecular Imaging Center Antwerp, University of Antwerp, Antwerp, Belgium.
Daniel C SullivanDepartment of Radiology, Duke University School of Medicine, Durham, NC.
Stuart A TaylorCRUK and EPSRC Cancer Imaging Centre at KCL and UCL, University College London, London, UK.
Paul S ToftsBrighton and Sussex Medical School, University of Sussex, Brighton, UK.
Gillian M TozerDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Marcel van HerkRadiotherapy Related Research Group, University of Manchester, Manchester, UK.
Simon Walker-SamuelCentre for Advanced Biomedical Imaging, University College London, London, UK.
James WasonMRC Biostatistics Unit, Cambridge, UK.
Kaye J WilliamsCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Manchester, Manchester, UK.
Paul WorkmanCRUK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK.
Thomas E YankeelovInstitute of Computational Engineering and Sciences, The University of Texas, Austin, TX.
Kevin M BrindleCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Cambridge, Cambridge, UK.
Lisa M McShaneBiometric Research Program, National Cancer Institute, Bethesda, MD.
Alan JacksonCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Manchester, Manchester, UK.
John C WatertonCRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester, University of Manchester, Manchester, UK.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MRadiomics of NSCLCU01CA143062 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GILLIES, ROBERT J., SCHABATH, MATTHEW B. · 2010 to 2020
$5.7MMultiscale Image-based Modeling of Antiangiogenic Resistance in Breast CancerR01CA196701 · NCI · JOHNS HOPKINS UNIVERSITY · PI Arvind P Pathak · 2015 to 2026
$3.6MCancer Research UK 10337Cancer Research UK 10342Cancer Research UK 10345Cancer Research UK 10348Cancer Research UK 11359Cancer Research UK 11562Cancer Research UK 11566Cancer Research UK 12011Cancer Research UK 15267Cancer Research UK 16049Cancer Research UK 16267Cancer Research UK 16463Cancer Research UK 16464Cancer Research UK 16465Cancer Research UK 16466Cancer Research UK 16584Cancer Research UK 16628Cancer Research UK 17242Cancer Research UK 18097Cancer Research UK 18974Cancer Research UK 19278Cancer Research UK 19908Cancer Research UK 20000Cancer Research UK 21993Cancer Research UK 22746Cancer Research UK 22897Cancer Research UK 8971Cancer Research UK 9993Department of Health EME/13/122/01Department of Health NIHR/CS/009/009Department of Health NIHR-RP-02-12-019Medical Research Council G0300648Medical Research Council G0700915Medical Research Council G0701533Medical Research Council MC_UP_1302/4Medical Research Council MR/J007986/1Medical Research Council MR/N020782/1NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA196701NCI NIH HHS U01 CA143062
Abstract
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
Indexed as
Biomarkers, TumorClinical Decision-MakingCost-Benefit AnalysisFluorodeoxyglucose F18Folic AcidHumansNeoplasmsOrganotechnetium CompoundsPositron-Emission TomographyPrognosisRadiopharmaceuticalsReproducibility of ResultsResearch DesignSelection BiasBiomarkers, TumorFluorodeoxyglucose F18Folic AcidOrganotechnetium CompoundsRadiopharmaceuticalstechnetium 99m etarfolatide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.